EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma

[1]  C. Stratakis,et al.  An update on the genetics of pheochromocytoma , 2013, Journal of Human Hypertension.

[2]  M. Soussan,et al.  Added value of early 18F-FDOPA PET/CT acquisition time in medullary thyroid cancer , 2012, Nuclear medicine communications.

[3]  J. Carrasquillo,et al.  Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. , 2012, Journal of the National Cancer Institute.

[4]  A. Al-nahhas,et al.  68Ga-labelled peptides in the management of neuroectodermal tumours , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  Rakesh Kumar,et al.  Prospective evaluation of 68Ga-DOTA-NOC PET-CT in phaeochromocytoma and paraganglioma: preliminary results from a single centre study , 2012, European Radiology.

[6]  P. Castaldi,et al.  Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  T. Fojo,et al.  False-negative ¹²³I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease. , 2012, Endocrine-related cancer.

[8]  C. Rottenburger,et al.  Is There an Optimal Scan Time for 6-[F-18]Fluoro-L-DOPA PET in Pheochromocytomas and Paragangliomas? , 2012, Clinical nuclear medicine.

[9]  E. Hindié,et al.  Modern Nuclear Imaging for Paragangliomas: Beyond SPECT , 2012, The Journal of Nuclear Medicine.

[10]  W. Linehan,et al.  Clinical utility of functional imaging with ¹⁸F-FDOPA in Von Hippel-Lindau syndrome. , 2012, The Journal of clinical endocrinology and metabolism.

[11]  H. Balon.  Updated Practice Guideline for Somatostatin Receptor Scintigraphy , 2011, The Journal of Nuclear Medicine.

[12]  E. Krenning,et al.  The SNM Practice Guideline for Somatostatin Receptor Scintigraphy 2.0* , 2011, The Journal of Nuclear Medicine Technology.

[13]  A. Celler,et al.  Patient-Specific Radiation Dosimetry of 99mTc-HYNIC-Tyr3-Octreotide in Neuroendocrine Tumors , 2011, The Journal of Nuclear Medicine.

[14]  E. Hindié,et al.  Modern PET imaging for paragangliomas: relation to genetic mutations. , 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[15]  D. Rubello,et al.  68Ga-DOTA-TATE PET vs. 123I-MIBG in Identifying Malignant Neural Crest Tumours , 2011, Molecular Imaging and Biology.

[16]  A. Vénisse,et al.  Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. , 2011, Human molecular genetics.

[17]  N. Patronas,et al.  Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy. , 2011, The Journal of clinical endocrinology and metabolism.

[18]  S. Robinson,et al.  Evaluation of LMI1195, a Novel 18F-Labeled Cardiac Neuronal PET Imaging Agent, in Cells and Animal Models , 2011, Circulation. Cardiovascular imaging.

[19]  P. Castaldi,et al.  Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma , 2011, Nuclear medicine communications.

[20]  V. Ambrosini,et al.  Incidence of Increased 68Ga-DOTANOC Uptake in the Pancreatic Head in a Large Series of Extrapancreatic NET Patients Studied with Sequential PET/CT , 2011, The Journal of Nuclear Medicine.

[21]  P. Span,et al.  Overexpression of the natural antisense hypoxia-inducible factor-1alpha transcript is associated with malignant pheochromocytoma/paraganglioma. , 2011, Endocrine-related cancer.

[22]  C. Nanni,et al.  I-123 MIBG scintigraphy and 68Ga-DOTANOC PET/CT negative but F-18 DOPA PET/CT positive pheochromocytoma: a case report. , 2011, Clinical nuclear medicine.

[23]  A. Tischler,et al.  Increased uptake of [¹²³I]meta-iodobenzylguanidine, [¹⁸F]fluorodopamine, and [³H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors. , 2011, Endocrine-related cancer.

[24]  A. Barlier,et al.  Comparison of [111In]pentetreotide‐SPECT and [18F]FDOPA‐PET in the localization of extra‐adrenal paragangliomas: the case for a patient‐tailored use of nuclear imaging modalities , 2011, Clinical endocrinology.

[25]  Agnieszka Maliszewska,et al.  Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. , 2010, Molecular endocrinology.

[26]  W. Oyen,et al.  Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[27]  P. Bartenstein,et al.  6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression. , 2010, The Journal of clinical endocrinology and metabolism.

[28]  I. Kema,et al.  Dopamine excess in patients with head and neck paragangliomas. , 2010, Anticancer research.

[29]  M. Bergström,et al.  In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours--impact of peptide mass. , 2010, Nuclear medicine and biology.

[30]  R. Dullaart,et al.  New imaging approaches to phaeochromocytomas and paragangliomas , 2010, Clinical endocrinology.

[31]  F. Mottaghy,et al.  Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[32]  M. Whatley,et al.  The use of functional imaging in a patient with head and neck paragangliomas. , 2010, The Journal of clinical endocrinology and metabolism.

[33]  W. Oyen,et al.  FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[34]  E. D. de Vries,et al.  6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. , 2009, The Journal of clinical endocrinology and metabolism.

[35]  P. Bénit,et al.  The Warburg Effect Is Genetically Determined in Inherited Pheochromocytomas , 2009, PloS one.

[36]  J. Carrasquillo,et al.  Use of 6‐[18F]‐fluorodopamine positron emission tomography (PET) as first‐line investigation for the diagnosis and localization of non‐metastatic and metastatic phaeochromocytoma (PHEO) , 2009, Clinical endocrinology.

[37]  A. Barlier,et al.  18F-FDG Avidity of Pheochromocytomas and Paragangliomas: A New Molecular Imaging Signature? , 2009, Journal of Nuclear Medicine.

[38]  J. Czernin,et al.  18F-FDOPA PET and PET/CT Accurately Localize Pheochromocytomas , 2009, Journal of Nuclear Medicine.

[39]  H. Dralle,et al.  The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT , 2009, European Radiology.

[40]  V. Ambrosini,et al.  Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET. , 2008, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[41]  H. Minn,et al.  The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors. , 2008, Endocrine-related cancer.

[42]  J. Carrasquillo,et al.  Comparison of 6-18F-Fluorodopamine PET with 123I-Metaiodobenzylguanidine and 111In-Pentetreotide Scintigraphy in Localization of Nonmetastatic and Metastatic Pheochromocytoma , 2008, Journal of Nuclear Medicine.

[43]  A. Barlier,et al.  The role of 18F‐FDOPA and 18F‐FDG–PET in the management of malignant and multifocal phaeochromocytomas , 2008, Clinical endocrinology.

[44]  I. Kema,et al.  111In-Octreotide Is Superior to 123I-Metaiodobenzylguanidine for Scintigraphic Detection of Head and Neck Paragangliomas , 2008, Journal of Nuclear Medicine.

[45]  K. Rahbar,et al.  Discrepancy between glucose metabolism and sympathetic nerve terminals in a patient with metastatic paraganglioma , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[46]  J. Carrasquillo,et al.  The Effects of Carbidopa on Uptake of 6-18F-Fluoro-l-DOPA in PET of Pheochromocytoma and Extraadrenal Abdominal Paraganglioma , 2007, Journal of Nuclear Medicine.

[47]  M. Gurnell,et al.  The use of 18-fluoro-dihydroxyphenylalanine and 18-fluorodeoxyglucose positron emission tomography scanning in the assessment of metaiodobenzylguanidine-negative phaeochromocytoma. , 2007, European journal of endocrinology.

[48]  J. Carrasquillo,et al.  Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  P. Gishen,et al.  68Ga-DOTATATE PET in neuroectodermal tumours: First experience , 2007, Nuclear medicine communications.

[50]  P. Pinto,et al.  The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome. , 2007, European journal of endocrinology.

[51]  G. Stamp,et al.  Expression of HIF-1α, HIF-2α (EPAS1), and Their Target Genes in Paraganglioma and Pheochromocytoma with VHL and SDH Mutations , 2006 .

[52]  K. Juergens,et al.  Whole-body PET/CT with 11C-meta-hydroxyephedrine in tumors of the sympathetic nervous system: feasibility study and comparison with 123I-MIBG SPECT/CT. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[53]  Hans-Georg Buchholz,et al.  Modulation of [18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge , 2006, NeuroImage.

[54]  Z. Win,et al.  The possible role of 68Ga-DOTATATE PET in malignant abdominal paraganglioma , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[55]  J. Reubi,et al.  68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5 , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[56]  V. Camacho,et al.  Challenging the neuronal MIBG uptake by pharmacological intervention: effect of a single dose of oral amitriptyline on regional cardiac MIBG uptake , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[57]  F. Grünwald,et al.  Case report: drug interference with MIBG uptake in a patient with metastatic paraganglioma. , 2004, The British journal of radiology.

[58]  F. Telischi,et al.  Octreotide Scintigraphy in the Head and Neck , 2004, The Laryngoscope.

[59]  H. Engler,et al.  Pheochromocytomas: detection with 11C hydroxyephedrine PET. , 2004, Radiology.

[60]  W. Oyen,et al.  111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[61]  P. Herman,et al.  Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[62]  R. Gilbert,et al.  Does Catecholamine Secretion from Head and Neck Paragangliomas Respond to Radiotherapy? Case Report and Literature Review. , 2003, Skull base : official journal of North American Skull Base Society ... [et al.].

[63]  J. Carrasquillo,et al.  Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. , 2003, The Journal of clinical endocrinology and metabolism.

[64]  B. Bernard,et al.  DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[65]  H. Ulmer,et al.  An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[66]  J. Schipper,et al.  18F-DOPA positron emission tomography for the detection of glomus tumours , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[67]  M. Dietlein,et al.  Clinical value of somatostatin receptor imaging in patients with suspected head and neck paragangliomas , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[68]  H. Neumann,et al.  Pheochromocytomas: detection with 18F DOPA whole body PET--initial results.. , 2002, Radiology.

[69]  S. Hasegawa,et al.  Metastases of predominantly dopamine-secreting phaeochromocytoma that did not accumulate meta-iodobenzylguanidine: imaging with whole body positron emission tomography using 18F-labelled deoxyglucose. , 2001, The European journal of surgery = Acta chirurgica.

[70]  Graeme Eisenhofer,et al.  6-[18F]Fluorodopamine Positron Emission Tomographic (PET) Scanning for Diagnostic Localization of Pheochromocytoma , 2001, Hypertension.

[71]  J. Reubi,et al.  Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use , 2000, European Journal of Nuclear Medicine.

[72]  F. Telischi,et al.  Octreotide scintigraphy for the detection of paragangliomas , 2000, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[73]  E. Krenning,et al.  Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[74]  A. D. Roberts,et al.  Fluorine-18-fluoro-L-DOPA dosimetry with carbidopa pretreatment. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[75]  J. Llamas-Elvira,et al.  111In-pentetreotide scintigraphy is superior to 123I-MIBG scintigraphy in the diagnosis and location of chemodectoma. , 1998, Nuclear medicine communications.

[76]  K. Endo,et al.  Radiation dosimetry for indium-111-pentetreotide. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[77]  T. Ishikawa,et al.  Bladder wall radiation dose in humans from fluorine-18-FDOPA. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[78]  C. Hoefnagel,et al.  Interference of MIBG uptake by medication: a case report. , 1995, The Netherlands journal of medicine.

[79]  M. Zalutsky,et al.  Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[80]  E. Krenning,et al.  Dopamine-producing paraganglioma not visualized by iodine-123-MIBG scintigraphy. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[81]  P. Voûte,et al.  Uptake of the neuron‐blocking agent meta‐iodobenzylguanidine and serotonin by human platelets and neuro‐adrenergic tumour cells , 1993, International journal of cancer.

[82]  N Satyamurthy,et al.  Regioselective radiofluorodestannylation with [18F]F2 and [18F]CH3COOF: a high yield synthesis of 6-[18F]Fluoro-L-dopa. , 1992, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

[83]  J. Bomanji,et al.  A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). , 1992, Nuclear medicine communications.

[84]  D. Kuhl,et al.  PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[85]  E P Krenning,et al.  Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[86]  L. Fig,et al.  Alterations of iodine-131 MIBG biodistribution in an anephric patient: comparison to normal and impaired renal function. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[87]  P. Harris,et al.  Pre- and post‐treatment distribution pattern of 123I‐MIBG in patients with phaeochromocytomas and paragangliomas , 1989, Nuclear medicine communications.

[88]  L. Fig,et al.  Labetalol reduces iodine-131 MIBG uptake by pheochromocytoma and normal tissues. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[89]  J. Sisson,et al.  Sodium dependency of uptake of norepinephrine and m-iodobenzylguanidine into cultured human pheochromocytoma cells: evidence for uptake-one. , 1987, Cancer research.

[90]  D. Levison,et al.  Uptake of iodine-123 MIBG by pheochromocytomas, paragangliomas, and neuroblastomas: a histopathological comparison. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[91]  G. Firnau,et al.  Estimation of the radiation dose in man due to 6-[18F]fluoro-L-dopa. , 1985, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[92]  C. Nahmias,et al.  Striatal dopamine metabolism in living monkeys examined by positron emission tomography , 1983, Brain Research.

[93]  F. Bidault,et al.  Fluorodesoxyglucose uptake in the remaining adrenal glands during the follow-up of patients with adrenocortical carcinoma: do not consider it as malignancy. , 2011, European journal of endocrinology.

[94]  J Nucl Med , 2010 .

[95]  J. Carrasquillo,et al.  Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. , 2009, The Journal of clinical endocrinology and metabolism.

[96]  G. Stamp,et al.  Expression of HIF-1alpha, HIF-2alpha (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations. , 2006, The Journal of clinical endocrinology and metabolism.

[97]  Paul Kinahan,et al.  Fluorodeoxyglucose Positron Emission Tomography Improve Clinical Decision Making in Suspected Pheochromocytoma , 2006 .

[98]  A. Hellwig,et al.  Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer. Eur J Nucl Med Mol Imaging , 2006 .

[99]  J. Fleming,et al.  Modification by nifedipine of 131I-meta-iodobenzylguanidine kinetics in malignant phaeochromocytoma , 2004, European Journal of Nuclear Medicine.

[100]  L. Mortelmans,et al.  131I/123I-Metaiodobenzylguanidine (MIBG) scintigraphy: procedure guidelines for tumour imaging , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[101]  H. Bonjer,et al.  [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas. , 2001, The Journal of clinical endocrinology and metabolism.

[102]  J. J. Mukherjee,et al.  The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[103]  B. Caillou,et al.  Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[104]  P. Merlet,et al.  Preparation and pharmacological characterization of [76Br]-meta-bromobenzylguanidine ([76Br]MBBG). , 1994, Nuclear medicine and biology.

[105]  M E Phelps,et al.  Remote, semiautomated production of 6-[18F]fluoro-L-dopa for human studies with PET. , 1990, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.